Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The INO news feed on Stock Titan aggregates company-issued press releases, regulatory updates, and other market-moving disclosures so readers can follow how INOVIO’s DNA medicine programs progress over time.
A major focus of recent INOVIO news is INO-3107, an investigational DNA medicine for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract. Updates include completion of a rolling Biologics License Application (BLA), FDA acceptance of the BLA for review under a Standard classification, and discussion of the accelerated approval pathway. News items also highlight clinical data showing reductions in the number of surgeries required by trial participants and long-term durability results from retrospective analyses.
Investors can also find announcements on capital-raising transactions, such as underwritten public offerings of common stock and warrants disclosed in Form 8-K filings and related press releases. INOVIO frequently reports on financial results, including quarterly earnings releases, as well as corporate governance and compensation matters like inducement stock option grants under its Inducement Plan.
Additional coverage includes scientific and clinical milestones, such as publication of Phase 1 proof-of-concept data for DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine and preclinical progress in DNA-encoded protein (DPROT) programs. Conference participation and investor events are also regular topics. For followers of INO stock, this news page offers a centralized view of the company’s clinical, regulatory, financial, and strategic communications.
Geneos Therapeutics announced the closure of its Series A1 financing round, raising $12 million. The funding, led by Korea Investment Partners, will be used to expand the GT-30 clinical trial for the GNOS-PV02 personalized cancer vaccine targeting hepatocellular carcinoma. The trial's patient enrollment has increased from 12 to 24. The investment indicates strong confidence in Geneos' GT-EPIC platform, designed for individualized cancer treatments. Additionally, Geneos has expanded its leadership team, enhancing its capacity for biopharmaceutical development.
INOVIO (NASDAQ: INO) reported Q4 2020 revenue of $5.6 million, up from $279,000 YoY, with a net loss of $24.3 million, compared to $37.7 million in Q4 2019. The company achieved efficacy endpoints in the Phase 3 REVEAL 1 trial for VGX-3100 and completed enrollment for the Phase 2/3 INNOVATE COVID-19 vaccine trial. Additionally, INOVIO entered a collaboration for INO-4800 in Greater China, potentially receiving up to $108 million. They are also developing next-gen COVID vaccines addressing emerging variants.
INOVIO (NASDAQ: INO) announced positive results from the REVEAL 1 Phase 3 trial for its DNA-based immunotherapy VGX-3100, targeting HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL). The trial achieved statistical significance for the primary endpoint, with a 23.7% response rate in the treatment group compared to 11.3% in the placebo group (p=0.022). All secondary endpoints were also met. There were no serious treatment-related adverse events. INOVIO plans to continue development and follow subjects for safety over 18 months.
INOVIO Pharmaceuticals (NASDAQ: INO) and QIAGEN (NYSE: QGEN) have extended their partnership to develop liquid biopsy-based companion diagnostics utilizing next-generation sequencing (NGS) technology. This collaboration focuses on a diagnostic test to identify women likely to benefit from INOVIO's VGX-3100, an immunotherapy for advanced cervical dysplasia linked to HPV. VGX-3100 is currently undergoing two Phase 3 trials, aiming to be the first non-surgical treatment for this condition. QIAGEN's expertise in bioinformatics will enhance the predictive capability of the diagnostic test.
QIAGEN and INOVIO Pharmaceuticals have extended their partnership with a master collaboration agreement to develop liquid biopsy-based diagnostic products utilizing next-generation sequencing (NGS) technology. The initial project will focus on a diagnostic test for identifying women who may benefit from VGX-3100, INOVIO's immunotherapy for advanced cervical dysplasia linked to HPV. This test will leverage QIAGEN’s bioinformatics to enhance INOVIO’s biomarker signature and will be developed for the Illumina NextSeq 550Dx platform, following a partnership established in 2019.
INOVIO (NASDAQ:INO) has initiated the first Phase 1B clinical trial for its DNA vaccine candidate, INO-4500, aimed at combatting Lassa fever in Ghana. This marks the first human trial for a Lassa fever vaccine in West Africa, an area heavily impacted by the disease. The trial, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), will involve 220 participants to assess safety and immunogenicity. INO-4500 has shown promising immune responses in prior trials. Successful advancement could lead to emergency stockpiling post-Phase 2 evaluation.
INOVIO (NASDAQ: INO) will release its fourth quarter and year-end 2020 financial results on March 1, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide updates on the company's DNA Medicines Platform, particularly its COVID-19 vaccine development. INOVIO, a pioneer in DNA medicines, is advancing clinical trials for its lead candidate VGX-3100, which targets precancerous cervical dysplasia linked to high-risk HPV types 16 and 18.
INOVIO Pharmaceuticals (Nasdaq: INO) has successfully closed its underwritten public offering of 20,355,000 shares at $8.50 each, generating approximately $173 million in gross proceeds. This includes an additional 2,655,000 shares purchased due to the underwriters' full exercise of their option. The offering was executed under an automatically effective shelf registration statement filed with the SEC on January 20, 2021. Funds from this offering are expected to enhance INOVIO's capabilities in developing DNA medicines for infectious diseases and cancer.
INOVIO Pharmaceuticals (Nasdaq: INO) announced the pricing of an underwritten public offering of 17.7 million shares of common stock at $8.50 per share, expected to yield approximately $150.5 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 2.655 million shares. Proceeds will support clinical development, including INO-4800, and general corporate purposes. The offering is anticipated to close on January 25, 2021, following customary conditions. This offering was registered with the SEC and aims to advance INOVIO's DNA medicine pipeline.
INOVIO Pharmaceuticals announced a public offering of $150 million in common stock, with plans to grant underwriters a 30-day option for an additional 15%. Proceeds will fund clinical development, specifically for INO-4800, and cover general corporate expenses. BofA Securities, Jefferies, and Cantor are managing the offering. This follows their shelf registration statement filed with the SEC, effective January 20, 2021. The offering is subject to market conditions, and there are no guarantees regarding its completion.